SanBio Company Limited Logo

SanBio Company Limited

Developing regenerative cell therapies for severe neurological disorders like brain injury and stroke.

4592 | T

Overview

Corporate Details

ISIN(s):
JP3336750009
LEI:
Country:
Japan
Address:
中央区明石町8番1号
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

SanBio Company Limited is a biotechnology firm dedicated to the research, development, production, and commercialization of regenerative cell medicines. The company focuses on creating novel treatments for severe neurological disorders, aiming to restore functions lost due to injury or disease. Its primary pipeline targets conditions affecting the central nervous system, such as chronic motor deficits resulting from traumatic brain injury and stroke. SanBio's lead product candidate, SB623 (marketed in Japan as AKUUGO®), is an allogeneic cell therapy developed to improve motor function in patients. The company leverages its proprietary technology for large-scale production to address significant unmet medical needs in neurology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 01:00
Share Issue/Capital Change
訂正臨時報告書
Japanese 31.2 KB
2025-09-12 08:31
Regulatory Filings
確認書
Japanese 7.9 KB
2025-09-12 08:31
Interim / Quarterly Report
半期報告書-第13期(2025/02/01-2026/01/31)
Japanese 230.6 KB
2025-06-13 08:45
Regulatory Filings
臨時報告書
Japanese 19.2 KB
2025-04-24 08:31
AGM Information
臨時報告書
Japanese 23.7 KB
2025-04-23 08:31
Registration Form
確認書
Japanese 8.0 KB
2025-04-23 08:31
Governance Information
内部統制報告書-第12期(2024/02/01-2025/01/31)
Japanese 21.6 KB
2025-04-23 08:30
Annual Report
有価証券報告書-第12期(2024/02/01-2025/01/31)
Japanese 1.3 MB
2025-03-17 07:30
Earnings Release
臨時報告書
Japanese 21.2 KB
2025-02-14 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 168.5 KB
2024-12-25 07:30
Regulatory Filings
臨時報告書
Japanese 19.3 KB
2024-12-02 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 112.5 KB
2024-09-17 08:02
Regulatory Filings
臨時報告書
Japanese 19.0 KB
2024-09-17 08:01
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-09-17 08:01
Interim / Quarterly Report
半期報告書-第12期(2024/02/01-2024/07/31)
Japanese 181.0 KB

Automate Your Workflow. Get a real-time feed of all SanBio Company Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SanBio Company Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SanBio Company Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NanoGroup S.A. Logo
Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.
Poland
NNG
NANO MRNA Co.,Ltd. Logo
Biotech IP generator developing and licensing mRNA therapeutics using proprietary delivery systems.
Japan
4571
NANOVIRICIDES, INC. Logo
Developing biomimetic nanomachines as broad-spectrum drugs to neutralize viral infections.
United States of America
NNVC
Nautilus Biotechnology, Inc. Logo
Developing a proteomics platform for single-molecule analysis to advance life sciences research.
United States of America
NAUT
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
Neovacs Logo
Develops immunotherapy vaccines for autoimmune diseases & invests in BioTech/MedTech companies.
France
ALNEV
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel
NXGN
NEXTURNBIOSCIENCE Co., LTD Logo
South Korea
089140
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions.
France
ALNFL

Talk to a Data Expert

Have a question? We'll get back to you promptly.